About this trial
A prospective, randomized controlled trial of fibrinogen concentrate (FC) plus standard of care versus standard of care alone in adult trauma patients with major bleeding or presumed major bleeding is developed to evaluate the efficacy and safety of prehospital administration of FC in trauma patients with suspected hypofibrinogenemia and active bleeding or presumed to be bleeding.
The main endpoints are:
1. Plasma fibrinogen levels in the first blood sample drawn at the patient's arrival at the trauma room and/or similar emergency bay dedicated to trauma and reanimation above the critical threshold of 2.0 g/l. As fibrinogen decreases early in trauma, its deficiency predicts massive bleeding and death. 2. Administration feasibility of FC within the prehospital setting.
Patients will be randomly assigned to receive either standard trauma care or standard trauma care plus administration of FC.
Eligibility criteria
Qualifiers
None
Disqualifiers
Known adverse reactions to fibrinogen concentrate (FC)
Isolated trauma such as traumatic head injury only
Need for cardiopulmonary resuscitation (CPR) on the scene or peri-arrest scenarios
Deep hypothermia
Trial design
Treatments tested in this trial
- Fibrinogen concentrate
- Standard trauma care
Treatment groups
Locations
Sponsors and collaborators
Unidade Local de Saude do Arco Ribeirinho
Lead sponsor
Unidade Local de Saúde de São José
Collaborator
Unidade Local de Saúde da Arrábida
Collaborator
Unidade Local de Saúde Santa Maria
Collaborator
Unidade Local de Saúde Almada-Seixal
Collaborator